Welcome to our dedicated page for Revvity news (Ticker: RVTY), a resource for investors and traders seeking the latest updates and insights on Revvity stock.
Revvity, Inc. reports developments for a global life sciences and diagnostics business that provides health science solutions, technologies, expertise and services across workflows from discovery and development to detection and diagnosis. Company updates center on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and Signals software for pharmaceutical, biotechnology, diagnostic laboratory, academic and government customers.
Recurring announcements include financial results and earnings calls, quarterly dividends, investor conference presentations, governance matters and product introductions. Recent product themes include Signals BioDesign for biologics construct design and research collaboration, Signals One platform integration, high-content imaging, multimode detection, sample preparation, screening and laboratory automation systems.
Revvity (NYSE: RVTY) announced a collaboration with Eli Lilly to make Lilly TuneLab predictive models available through the Signals Xynthetica offering, creating a federated framework to accelerate AI-enabled drug discovery. The integration lets participating biotechs apply Lilly’s models inside the Signals platform while keeping proprietary data private via federated learning and Revvity’s Models-as-a-Service approach. Revvity’s Signals One and Signals Synergy modules provide data capture, analytics, and secure exchange to support the network. Lilly and Revvity will jointly fund access for selected participants, including software access and modeling credits, aimed at lowering barriers to AI adoption across the biotech ecosystem.
Revvity (NYSE: RVTY) will present at the 44th annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:45 a.m. PT. President and CEO Prahlad Singh will provide an update on the company and its strategic priorities. A live audio webcast will be available in the Events section of the company website, and a replay will be posted on the Revvity Investor Relations site and available for at least 30 days.
Revvity (NYSE: RVTY) announced Signals Xynthetica, a forthcoming AI Models-as-a-Service within the Revvity Signals platform that integrates in-silico molecular and materials design with experimental validation in a governed environment. The offering supports de novo generation, property prediction, and multi-objective optimization while enabling model governance, refreshes, and transparent evaluation alongside wet-lab results.
Revvity said pre-registration is open and early access programs begin in 1H 2026, positioning Signals Xynthetica as part of Revvity’s vision for AI-augmented discovery.
Revvity (NYSE: RVTY) entered into a definitive agreement to acquire ACD/Labs, a provider of scientific software for analytical characterization and molecular design. The transaction is expected to close late in Q4 2025. ACD/Labs products named in the announcement include Spectrus (spectral analysis), Percepta (AI molecular property and ADMET prediction), Katalyst D2D, Luminata, and ADMS.
The deal is positioned to expand Revvity Signals across discovery, development, scale-up, and manufacturing workflows and create a unified SaaS environment linking molecular design, analytical science, and quality control. Management noted customary forward-looking risks, including integration and market uncertainties.
Revvity (NYSE: RVTY) will present at three investor conferences in November–December 2025 with senior executives providing company updates and strategic priorities.
Schedule: UBS Global Healthcare Conference on Nov 10, 2025 at 8:00 a.m. ET (Max Krakowiak, SVP & CFO); Jefferies London Healthcare Conference on Nov 18, 2025 at 2:00 p.m. GMT (Max Krakowiak); and Citi Global Healthcare Conference on Dec 2, 2025 at 9:00 a.m. ET (Prahlad Singh, president & CEO).
Events are fireside chats; live audio webcasts will stream on the company Events page and replays will be posted to Revvity investor relations for at least 30 days.
Revvity (NYSE: RVTY) reported Q3 2025 results for the quarter ended September 28, 2025: revenue $699M (2% reported growth, 1% organic), GAAP EPS $0.40, and adjusted EPS $1.18. GAAP operating margin was 11.7%; adjusted operating margin was 26.1%. By segment, Life Sciences revenue was $343M (flat organic) and Diagnostics revenue was $356M (organic +2%).
The company reaffirmed 2025 organic growth guidance of 2%–4%, raised adjusted EPS guidance to $4.90–$5.00, and authorized a new $1 billion two-year share repurchase program. Management cited strategic partnerships and innovation as drivers for future execution.
Revvity (NYSE: RVTY) declared a regular quarterly dividend of $0.07 per share. The dividend is payable on February 6, 2026 to shareholders of record at the close of business on January 16, 2026.
Revvity (NYSE: RVTY) released its 2025 Impact Report, "Progress with Purpose: Science and Sustainability," summarizing sustainability, social and governance progress through 2024.
Key highlights include a 6% year-over-year reduction in Scope 1 and 2 emissions in 2024 (a 14% cumulative cut since 2022), 49% of non-hazardous waste diverted from landfills in 2024 (exceeding a 40% by-2027 target), and an AAA MSCI ESG rating. The report notes completion of a double materiality assessment and expansion of Revvity Access STEM Scholarships to global universities. The company also earned Great Place to Work recognition in multiple countries.
Revvity (NYSE: RVTY) will release its third-quarter 2025 financial results before market open on Monday, October 27, 2025. The company will hold a conference call the same day at 8:00 a.m. ET to discuss the results.
Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the call. A live audio webcast will be available in the Investors section of the company's website for access.
Revvity (NYSE:RVTY) has announced a significant program to expand its type 1 diabetes (T1D) testing capabilities, partnering with Sanofi. The initiative includes developing a T1D 4-plex in vitro diagnostic (IVD) assay based on their existing 3-plex research-use assay.
The program aims to enable population-scale screening for early-stage T1D using Revvity's GSP® instrument with both capillary dried blood spot and venous specimens. The company plans regulatory submissions to the U.S. FDA, IVDR, and other major jurisdictions. Additionally, Revvity will expand its laboratory network globally to increase access to its existing research-use product, currently offered as an LDT at their CLIA and CAP accredited Revvity Omics laboratory in Pittsburgh.
This initiative addresses a significant medical need, as over 9 million people worldwide live with T1D, with more than 500,000 new cases diagnosed annually, 90% without family history.